LEADER 00000cam  2200361Ii 4500 
001    ocn930255403 
003    OCoLC 
005    20160531031012.0 
008    151118s2016    flua          000 0 eng d 
019    929918065 
020    9781498748506|q(hardback) 
020    1498748503|q(hardback) 
035    (OCoLC)930255403|z(OCoLC)929918065 
040    BTCTA|beng|erda|cBTCTA|dYDXCP|dOCLCQ|dOCLCO|dBAL|dBDX|dSTJ
049    STJP 
050  4 RA401.A3|bP54 2016 
096    QV 32 AA1|bP536 2016 
245 00 Pharmaceutical public policy /|c[edited by] Thomas R. 
       Fulda, Alan Lyles, Albert I. Wertheimer. 
264  1 Boca Raton :|bCRC Press,|c[2016] 
300    xv, 497 pages :|billustrations ;|c26 cm 
336    text|btxt|2rdacontent 
337    unmediated|bn|2rdamedia 
338    volume|bnc|2rdacarrier 
500    "A Productivity Press book." 
520    "Pharmaceutical Public Policy provides the understanding 
       and framework required for effective organization, 
       financing, and delivery of pharmaceutical products and 
       services. It supplies an overview of the policy process as
       well as the roles of legislation and regulation in 
       pharmaceutical policy.The book identifies the goals, 
       objectives, and key policy issues of concern to 
       stakeholders involved in the development of products, use 
       of pharmaceuticals in healthcare, and administration of 
       insurance programs by both the private and government 
       sectors. Policy issues examined include the 
       appropriateness of prescribing and patient adherence. 
       Addressing questions of access, quality, and cost, the 
       book considers the operation of the Affordable Care Act 
       and Medicare Part D. It details the responsibilities of 
       Federal providers of pharmaceutical care and private and 
       public payers such as managed care organizations, pharmacy
       benefit managers, Medicare, and Medicaid. The book covers 
       the policies and practices involved in promoting 
       pharmaceutical products. It also considers 
       pharmacoeconomics as a response to market failure. Finally,
       the book describes the market, the role of the 
       manufacturer, drug shortages, and the responsibilities of 
       the FDA. " -- Publisher's description. 
650  0 Pharmaceutical policy|zUnited States. 
700 1  Fulda, Thomas R.,|eeditor. 
700 1  Lyles, Alan,|eeditor. 
700 1  Wertheimer, Albert I.,|eeditor. 
776 08 |iOnline version:|aFulda, Thomas R.|tPharmaceutical public
       policy.|dBoca Raton : CRC Press, 2016|z9781498748513
       |w(OCoLC)948247010 
994    C0|bSTJ